Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Diversify Advisory Services LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.3% during the ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

(Reuters) - Gilead Sciences and the U.S. government have settled ... and deliver innovative therapeutics to people with life-threatening diseases." Spokespeople for the U.S. Department of Health ...

Gilead Sciences, US Government Settle Patent Case ... and deliver innovative therapeutics to people with life-threatening diseases." Spokespeople for the U.S. Department of Health and Human ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion ... and deliver innovative therapeutics to people with life-threatening diseases." Spokespeople for the U.S. Department of ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...